Trials / Withdrawn

WithdrawnNCT00408967

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma

Status: Withdrawn
Phase: Phase 2
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: EMD Serono · Industry
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression

Conditions

Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Tucotuzumab celmoleukin (EMD 273066)

Timeline

Start date: 2006-12-31
Primary completion: 2008-05-31
Completion: 2008-05-31
First posted: 2006-12-08
Last updated: 2017-08-18

Source: ClinicalTrials.gov record NCT00408967. Inclusion in this directory is not an endorsement.